Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

NCT07061977 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07061977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07061977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Recruiting
Start date
November 5, 2025
Completion date
December 31, 2030
Enrollment
336 (estimated)
Sites
340

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced cervical adenocarcinoma, locally advanced cervical adenosquamous carcinoma, locally advanced cervical squamous cell carcinoma, stage iiia cervical cancer figo 2018, stage iiib cervical cancer figo 2018, stage iiic1 cervical cancer figo 2018, stage iiic2 cervical cancer figo 2018, stage iva cervical cancer figo 2018